After thoroughly establishing the specificity of these antibodies for their pathological targets, we use them to determine the relative distribution and abundance of different RAN derived proteins in the brains of FXTAS patients and their overlap with ubiquitin and p62 pathology in using blinded analysis to provide unbiased and rigorous results. This evidence concerns the gene SQSTM1 and fragile X-associated tremor/ataxia syndrome.